Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: A retrospective cohort study

Research output: Contribution to journalArticle

6 Citations (Scopus)


Purpose There have been reports that radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) is as equally effective as surgical resection for the treatment of hepatocellular carcinoma (HCC). This study aimed to evaluate recurrence rate and risk factor of recurrence after RFA combined with TACE for early stage HCC. Methods We reviewed the medical records of the patients who were diagnosed with early stage HCC between March 2006 and August 2008 at Korea University Medical Center and treated with RFA combined with TACE for curative intent (n = 65). Results Recurrence rate was 40% (26 cases) and the time to recurrence was 14.9 months. Cumulative recurrence rate at 1 year was 20% (13 cases) and at 2 years was 33.8% (22 cases). Significant variables for recurrence were: (1) RFA repeated more than one session at initial therapy (P\0.001) and (2) size of main lesion C2 cm(P = 0.047). Conclusions The recurrence rate of combination therapy was considerably high. Regardless of the therapy used, careful post-RFA follow-up is needed, especially if additional treatment is required after the first session or if the main lesion is C2 cm at the time of RFA.

Original languageEnglish
Pages (from-to)505-510
Number of pages6
JournalHepatology International
Issue number2
Publication statusPublished - 2012 Apr 1



  • Hepatocellular carcinoma
  • Radiofrequency ablation
  • Transarterial chemoembolization

ASJC Scopus subject areas

  • Hepatology

Cite this